Country: Canada
Language: English
Source: Health Canada
BLEOMYCIN (BLEOMYCIN SULFATE)
PFIZER CANADA ULC
L01DC01
BLEOMYCIN
15UNIT
POWDER FOR SOLUTION
BLEOMYCIN (BLEOMYCIN SULFATE) 15UNIT
INTRA-ARTERIAL
10ML VIAL
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0133328001; AHFS:
APPROVED
2002-12-02
PRODUCT MONOGRAPH PR BLEOMYCIN FOR INJECTION USP (as bleomycin sulphate) 15 UNITS OF BLEOMYCIN/VIAL Sterile Powder THERAPEUTIC CLASSIFICATION Antineoplastic agent Pfizer Canada Inc. 17300 Trans-Canada Highway Kirkland, Québec H9J 2M5 Control No.: 206646 Date of Revision: August 8, 2017 _Product Monograph - _ _Pr_ _Bleomycin_ _for Injection USP _ _Page 2 of 30_ PRODUCT MONOGRAPH PR BLEOMYCIN FOR INJECTION USP (as bleomycin sulphate) 15 units of bleomycin/vial Sterile Powder THERAPEUTIC CLASSIFICATION Antineoplastic Agent ACTION AND CLINICAL PHARMACOLOGY Experiments with isolated DNA have shown that bleomycin binds to the DNA molecule and cleaves it. This results in the inhibition of DNA synthesis. There is also evidence of lesser inhibition of RNA and protein synthesis. Bleomycin exhibits a wide spectrum of _in vitro_ and _in vivo_ activity. It demonstrates inhibition of DNA synthesis in _E. _ _coli, _ _B. _ _subtilis,_ Ehrlich ascites cells, HeLa cells, PHA-stimulated lymphocytes, L-929 fibroblasts, L5178Y cells and Novikoff hepatoma ascites cells, at concentrations within a general range of 4-20 microgram/mL under typical incubation conditions. The activity of bleomycin seems to be cell phase-specific. Cyclic and continuous administration of bleomycin has been shown to be more effective than bolus dosing in _in vivo_ systems. Bleomycin is well absorbed after parenteral (intravenous, subcutaneous, intramuscular, and intrapleural) but not after oral administration. Tissue distribution was evaluated in mice and was found to be high in skin, kidney, lung, peritoneum, lymphatics and solid tumour and tumour cells in ascites. Bleomycin does not cross the blood-brain barrier. _Product Monograph - _ _Pr_ _Bleomycin_ _for Injection USP _ _Page 3 of 30_ Several tissues have demonstrated a capacity to degrade bleomycin. The liver and GI tract show the highest rate of inactivation. The skin, lungs and kidney show a lower rate which may account for the site-specific toxicity of the drug. Bleomycin half-life varies with creat Read the complete document